Credit Suisse initiated coverage on GreenLight Biosciences with a new price target

10/14/22 7:27:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRNA

Date	Price Target	Rating	Analyst
12/8/2022	$4.00	Buy	Canaccord Genuity
10/14/2022	$5.50	Outperform	Credit Suisse